Commentary on "Evaluation of Major Pathologic Response and Pathologic Complete Response as Surrogate End Points for Survival in Randomized Controlled Trials of Neoadjuvant Immune Checkpoint Blockade in Resectable in NSCLC"
1 Section of Hematology/Oncology, University of Chicago Medicine, Chicago, Illinois; Division of Hematology/Oncology, Northwestern University, Chicago, Illinois; Department of Clinical Oncology, "Mario Negri" Institute for Pharmacological Research- IRCCS, Milan, Italy. Electronic address: [email protected].
2 Section of Hematology/Oncology, University of Chicago Medicine, Chicago, Illinois; Division of Hematology/Oncology, Northwestern University, Chicago, Illinois; Department of Clinical Oncology, "Mario Negri" Institute for Pharmacological Research- IRCCS, Milan, Italy.